Intranasal Therapeutics Inc., a Lexington, Ky.–based developer of nasally-delivered, preservative-free drug products, has raised $39.1 million in Series A funding. SV Life Sciences led the deal, and was joined by Burrill & Co., Tullis-Dickerson, Fidelity Biosciences, ApjohnVentures, Fort Washington Capital, Commonwealth Seed Capital and Kentucky Co-Investment Partners (U Kentucky). www.intranasal.com